ライフサイエンスコーパス: hematopoietic stem cell

1 ted genes, commonly occurs among aging human hematopoietic stem cells.

2 which facilitated their direct contact with hematopoietic stem cells.

3 graft-versus-host disease after transfer of hematopoietic stem cells.

4 rgets the bone marrow compartment, including hematopoietic stem cells.

5 stim to facilitate collection of circulating hematopoietic stem cells.

6 s to impairment of long-term self-renewal of hematopoietic stem cells.

7 tions within a seemingly homogenous group of hematopoietic stem cells.

8 p-dioxin on long-term self-renewal of murine hematopoietic stem cells.

9 The platform was used to deliver single hematopoietic stem cells.

10 ent, possibly directly stemming from infused hematopoietic stem cells.

11 drift acting on a small population of active hematopoietic stem cells.

12 ogical effects of Runx1 in the generation of hematopoietic stem cells.

13 l factor transgene were engrafted with human hematopoietic stem cells.

14 ntisickling beta-globin gene into autologous hematopoietic stem cells.

15 Humanized mice engrafted with human hematopoietic stem cells and developing functional human

16 EXTL3 was most abundant in hematopoietic stem cells and early progenitor T cells, w

17 he percentage of stromal cells, macrophages, hematopoietic stem cells and fibroadipogenic cells in th

18 ow progenitor analysis revealed depletion of hematopoietic stem cells and multipotent progenitors acr

19 nd to germ-free mice restored the numbers of hematopoietic stem cells and precursors in bone marrow a

20 tophagy on leukemic transformation of normal hematopoietic stem cells and summarizes its role on leuk

21 escence/cycling balance of murine short-term hematopoietic stem cells and their differentiation into

22 ( + ) mice, which conditionally lack ET-1 in hematopoietic stem cells and vascular endothelial cells,

23 ro, decreased expression of Hox genes in the hematopoietic stem cells, and decreased MLL occupancy at

24 NK cells develop from hematopoietic stem cells, and few monogenic errors that

25 o identify functional long-term repopulating hematopoietic stem cells, and has been detected in certa

26 vity of innate immune cells, mesenchymal and hematopoietic stem cells, and insulin-releasing pancreat

27 axis is involved in the interaction between hematopoietic stem cells (as well as hematologic and sol

28 e human chorion contains functionally mature hematopoietic stem cells at mid-gestation.

29 Most FA patients experience hematopoietic stem cell attrition and cytopenia during c

30 human fetal thymus, liver, and liver-derived hematopoietic stem cells (BLT mice).

31 -binding protein-2 (GATA-2) was expressed in hematopoietic stem cells, but not in NK-cell progenitors

32 Rapid clearance of administered porcine hematopoietic stem cells by primate macrophages has hamp

33 Definitive hematopoietic stem cells, capable of multilineage and lo

34 LC generated from CD34(+) hematopoietic stem cells (CD34LC) were treated with the

35 r the first time that optimized protocols of hematopoietic stem cell collection from FA patients, fol

36 ansfer genes specifically into the primitive hematopoietic stem cell compartment through the utilizat

37 ns of genes of interest from primary CD34(+) hematopoietic stem cells (cRBCs).

38 l-plastin; and disrupts the specification of hematopoietic stem cells (definitive hematopoiesis), as

39 dited CD34+ cells are long-term repopulating hematopoietic stem cells, demonstrating the potential of

40 iated with the rise of founding clones or of hematopoietic stem cells devoid of recurrent mutations.

41 Dormant hematopoietic stem cells (dHSCs) are atop the hematopoie

42 oth LANCL-2 and GRP78 is up-regulated during hematopoietic stem cell differentiation into mature mega

43 se group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnor

44 Myelodysplastic syndromes (MDSs) are hematopoietic stem cell disorders in which recurrent mut

45 upply in peripheral blood from Krt7-positive hematopoietic stem cells during unperturbed homeostatic

46 gut, brain, kidney and lungs of human CD34+ hematopoietic stem cell engrafted virus-infected NOD.Cg-

47 Primary hematopoietic stem cells expanded with cytokines were hy

48 Hematopoietic stem cells expressed both CD177 alleles an

49 The generation of hematopoietic stem cells from human pluripotent stem cel

50 uced vascular permeability, preserved normal hematopoietic stem cell function, and improved treatment

51 in BM-derived cells precipitates defects in hematopoietic stem cell function, contributing to extram

52 lobin expression, is required for immune and hematopoietic stem cell functions and brain development.

53 As p53 is central to hematopoietic stem cell functions, its aberrations affec

54 The pathway to generate T cells from hematopoietic stem cells guides progenitors through a su

55 factor expressed by myeloid-biased long term-hematopoietic stem cells, guides the lineage specificati

56 are present and expressed within a leukemic hematopoietic stem cell has engendered some controversy.

57 ently add new copies of the relevant gene to hematopoietic stem cells have led to safe and effective

58 Myeloablative treatment preceding hematopoietic stem cell (HSC) and progenitor cell (HS/PC

59 oproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (HSC) compartment as a result of

60 e tracked back to the phenotypically defined hematopoietic stem cell (HSC) compartment in all investi

61 the impact of obesity on the activity of the hematopoietic stem cell (HSC) compartment.

62 However, the function of MOF in hematopoietic stem cell (HSC) development has not yet be

63 (GFs) that together promote quiescent human hematopoietic stem cell (HSC) expansion ex vivo have bee

64 lethal fetal liver hematopoietic defects and hematopoietic stem cell (HSC) failure.

65 equences of adult-onset DR (24 h to 1 yr) on hematopoietic stem cell (HSC) function.

66 Thus, we developed a hematopoietic stem cell (HSC) gene therapy approach usin

67 Efficient hematopoietic stem cell (HSC) homing is important for he

68 linically to treat leukopenia and to enforce hematopoietic stem cell (HSC) mobilization to the periph

69 ulations that express characteristics of the hematopoietic stem cell (HSC) niche contain precursors t

70 ultimately orchestrated and sustained by the hematopoietic stem cell (HSC) niche.

71 EMH activation requires hematopoietic stem cell (HSC) proliferation and mobiliza

72 le bone marrow cells that regulate different hematopoietic stem cell (HSC) properties such as prolife

73 The role of osteolineage cells in regulating hematopoietic stem cell (HSC) regeneration following mye

74 s of Armcx1 and Gprasp2, whose loss enhanced hematopoietic stem cell (HSC) repopulation.

75 eptor (EPCR/CD201/PROCR) when exposed to the hematopoietic stem cell (HSC) self-renewal agonist UM171

76 ne marrow microenvironment (niche) regulates hematopoietic stem cell (HSC) self-renewal and commitmen

77 em declines with age, resulting in decreased hematopoietic stem cell (HSC) self-renewal capacity, mye

78 ietic-specific loss of Tet2 induces aberrant hematopoietic stem cell (HSC) self-renewal/differentiati

79 Hematopoietic stem cell (HSC) transplantation represents

80 n precedes, and is necessary for, successful hematopoietic stem cell (HSC) transplantation, the only

81 Chronic myeloid leukemia (CML) is a hematopoietic stem cell (HSC)-driven neoplasia character

82 dent transformation in MLL-CSCs derived from hematopoietic stem cell (HSC)-enriched LSK population bu

83 ch, we identify ZNF521/Zfp521 as a conserved hematopoietic stem cell (HSC)-enriched transcription fac

84 itive and erythromyeloid progenitor waves of hematopoietic stem cell (HSC)-independent hematopoiesis

85 herapy and show BCR-ABL1 positivity in their hematopoietic stem cell (HSC)/progenitor/myeloid compart

86 scRNA-seq on murine hematopoietic stem cells (HSC) and their progeny MPP1 se

87 Accumulation of damaged DNA in hematopoietic stem cells (HSC) is associated with chromo

88 ease in miR101c, which downregulated Tet1 in hematopoietic stem cells (HSC), resulting in reduced exp

89 ynamically drive mature cell production, and hematopoietic stem cells (HSC), which provide a quiescen

90 erved microRNAs that are highly expressed in hematopoietic stem cells (HSCs) and acute myeloid leukem

91 Bone marrow vascular niches sustain hematopoietic stem cells (HSCs) and are drastically remo

92 fects the maintenance and differentiation of hematopoietic stem cells (HSCs) and committed progenitor

93 with its receptor as a means of targeting MF hematopoietic stem cells (HSCs) and hematopoietic progen

94 RNA sequencing in Ezh2-deficient hematopoietic stem cells (HSCs) and megakaryocytic eryth

95 revious studies have revealed an increase in hematopoietic stem cells (HSCs) and multipotent progenit

96 o investigate the role of DDT in maintaining hematopoietic stem cells (HSCs) and progenitors, we used

97 -2 protein family member highly expressed in hematopoietic stem cells (HSCs) and regulated by growth

98 Not all hematopoietic stem cells (HSCs) are alike.

99 Hematopoietic stem cells (HSCs) are dormant in the bone

100 ormal globin-producing genes into autologous hematopoietic stem cells (HSCs) are in clinical trials f

101 Hematopoietic stem cells (HSCs) are mobilized from niche

102 Hematopoietic stem cells (HSCs) are responsible for life

103 Long-term repopulating (LT) hematopoietic stem cells (HSCs) are the most undifferent

104 Hematopoietic stem cells (HSCs) are the therapeutic comp

105 Hematopoietic stem cells (HSCs) can be safely collected

106 ould be greatly improved if patient-specific hematopoietic stem cells (HSCs) could be generated from

107 The maintenance of hematopoietic stem cells (HSCs) during ex vivo culture i

108 In the developing embryo, hematopoietic stem cells (HSCs) emerge from the aorta-go

109 Hematopoietic stem cells (HSCs) ensure a balanced produc

110 erve cancer but instead found that aneuploid hematopoietic stem cells (HSCs) exhibit decreased fitnes

111 nals that enhance the retention or egress of hematopoietic stem cells (HSCs) from bone marrow (BM).

112 Single hematopoietic stem cells (HSCs) have been functionally s

113 Hematopoietic stem cells (HSCs) have long been considere

114 Hematopoietic stem cells (HSCs) in the bone marrow (BM)

115 Damage to hematopoietic stem cells (HSCs) in the bone marrow was d

116 We observed that murine hematopoietic stem cells (HSCs) in which Dnmt3a had been

117 in some types of stem cell, but its role in hematopoietic stem cells (HSCs) is unknown.

118 Hematopoietic stem cells (HSCs) mature from pre-HSCs tha

119 Hematopoietic stem cells (HSCs) produce most cellular en

120 Prolonged exit from quiescence by hematopoietic stem cells (HSCs) progressively impairs th

121 Hematopoietic stem cells (HSCs) remain mostly quiescent

122 Hematopoietic stem cells (HSCs) reside at the top of the

123 r humanized through the engraftment of human hematopoietic stem cells (HSCs) that can lead to human h

124 rom a small population of disease-initiating hematopoietic stem cells (HSCs) that persist and expand

125 Hematopoietic stem cells (HSCs) that sustain lifelong bl

126 s (2016) determine the divisional history of hematopoietic stem cells (HSCs) to be a key player of re

127 we investigated its role in the response of hematopoietic stem cells (HSCs) to liver fibrosis in mic

128 e occurred in parallel with specification of hematopoietic stem cells (HSCs) to the myeloid and lymph

129 The use of allogeneic hematopoietic stem cells (HSCs) to treat genetic blood c

130 Upon aging, hematopoietic stem cells (HSCs) undergo changes in funct

131 CRISPR/Cas9-corrected iPSC-derived hematopoietic stem cells (HSCs) were injected into suble

132 Inflammatory signals can activate hematopoietic stem cells (HSCs), but how HSCs regain qui

133 However, in hematopoietic stem cells (HSCs), FOXO3A is largely local

134 xt of hematopoiesis, and specifically within hematopoietic stem cells (HSCs), have not clearly been d

135 or and tightly controls cardinal features of hematopoietic stem cells (HSCs), including self-renewal,

136 is not known if adult LCH or ECD arises from hematopoietic stem cells (HSCs), nor which potential blo

137 ic homeostasis depends on the maintenance of hematopoietic stem cells (HSCs), which are regulated wit

138 sue and cells that regulates the behavior of hematopoietic stem cells (HSCs).

139 increased numbers of phenotypically defined hematopoietic stem cells (HSCs).

140 attributed to cell-intrinsic alterations in hematopoietic stem cells (HSCs); however, the contributi

141 tors that can amplify long-term repopulating hematopoietic stem cells in a controlled way.

142 als evaluating the activity of gene-modified hematopoietic stem cells in conferring resistance to HIV

143 ilar to their healthy counterpart, malignant hematopoietic stem cells in myeloid malignancies, such a

144 , reduced regeneration of leukemic long-term hematopoietic stem cells in secondary transplant recipie

145 al vessels and altered population balance of hematopoietic stem cells in the bone marrow, manifested

146 transferring a GFP reporter gene into adult hematopoietic stem cells in vivo, which are predominantl

147 Differentiation of hematopoietic stem cells into distinct cell types was th

148 Transplantation of a single hematopoietic stem cell is an important method for its f

149 lood cells is derived from a single dominant hematopoietic stem cell lineage.

150 n defect, erythroid dysplasia, and long-term hematopoietic stem cell (LT-HSC) expansion.

151 enance and functional integrity of long-term hematopoietic stem cells (LT-HSCs) is critical for lifel

152 ) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR

153 bility, indicating that Erf is necessary for hematopoietic stem cell maintenance or differentiation.

154 Myeloid-biased hematopoietic stem cells (MB-HSCs) play critical roles i

155 one marrow, where they presumably hijack the hematopoietic stem cell niche.

156 mbination with other cell therapies (such as hematopoietic stem cells or bone marrow-derived MSC or d

157 lines can be efficiently differentiated into hematopoietic stem cell precursors, as well as APC, unde

158 e lesions, resulted in the perinatal loss of hematopoietic stem cells, progressive loss of bone marro

159 such as CD33 and CD123, is not expressed on hematopoietic stem cells providing potential hematopoiet

160 Hematopoietic stem cells receive the regulatory signals

161 Adoptive transfer of WT bone marrow-derived hematopoietic stem cells reconstituted c-kit but not MAT

162 Adhesion is a key component of hematopoietic stem cell regulation mediating homing and

163 gents paired with cell populations including hematopoietic stem cells, regulatory T cells, and facili

164 Additionally, inhibition of ARID3a in hematopoietic stem cells resulted in altered expression

165 evealed that transformed MEPs gain a partial hematopoietic stem cell signature and largely retain an

166 the blood program during development, adult hematopoietic stem cell survival and quiescence, and ter

167 mice engrafted with human thymus, liver, and hematopoietic stem cells (termed Bone marrow, Liver, Thy

168 able to engraft murine recipients with human hematopoietic stem cells that develop into functional hu

169 to the embryonic development and function of hematopoietic stem cells that form the adult hierarchy,

170 or maintaining the replicative quiescence of hematopoietic stem cells throughout life by limiting the

171 istinctive feature of neoplastic B cells and hematopoietic stem cells, thus identifying ILT3 as a sel

172 , Wu et al. use genetic barcoding of macaque hematopoietic stem cells to demonstrate that, after tran

173 to the peripheral immune system that biases hematopoietic stem cells to differentiate into a glucoco

174 iew highlights recent advances in the use of hematopoietic stem cells to facilitate genetic screening

175 immunogenicity results of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and

176 is widely used as a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

177 needs in the fields of both solid-organ and hematopoietic stem cell transplant (HCT).

178 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are s

179 (CMV) retinitis in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is

180 ratory virus detected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in

181 survival and stabilize cerebral disease is a hematopoietic stem cell transplant (HSCT).

182 sed morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT).

183 sease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients.

184 ific T cells and viral control in allogeneic hematopoietic stem cell transplant recipients.

185 versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex im

186 lity of life (QOL) and symptom burden during hematopoietic stem-cell transplant (HCT).

187 representing 664 admissions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2

188 ents receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant

189 ses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSCT), but can

190 -versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by su

191 intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo-HCT) recip

192 have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in c

193 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a

194 ent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), who

195 of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

196 has not been investigated during allogeneic hematopoietic stem cell transplantation (allo-HSCT).

197 t-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is pot

198 elapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT) failure, a

199 Importance: During hospitalization for hematopoietic stem cell transplantation (HCT), patients

200 n transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT) and enter

201 Autologous hematopoietic stem cell transplantation (HSCT) and mesen

202 virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT) are a maj

203 Neurological complications (NC) after hematopoietic stem cell transplantation (HSCT) are rare

204 common and poorly recognized complication of hematopoietic stem cell transplantation (HSCT) associate

205 ry of CMV-specific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could ass

206 Hematopoietic stem cell transplantation (HSCT) cures the

207 ity conditioning has improved survival after hematopoietic stem cell transplantation (HSCT) for hemop

208 Allogeneic hematopoietic stem cell transplantation (HSCT) from an H

209 anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not b

210 ion developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelod

211 Allogeneic hematopoietic stem cell transplantation (HSCT) is a crit

212 Hematopoietic stem cell transplantation (HSCT) is an imp

213 Allogeneic hematopoietic stem cell transplantation (HSCT) is used a

214 Autologous hematopoietic stem cell transplantation (HSCT) of gene-m

215 Hematopoietic stem cell transplantation (HSCT) offers cu

216 Allogeneic hematopoietic stem cell transplantation (HSCT) remains t

217 Hematopoietic stem cell transplantation (HSCT) represent

218 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monit

219 rophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing

220 is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and upda

221 ely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least

222 t and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT), posing a

223 han the general population, especially after hematopoietic stem cell transplantation (HSCT).

224 y and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT).

225 cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT).

226 uccessfully underwent a sequential liver and hematopoietic stem cell transplantation (HSCT).

227 a significant burden in patients undergoing hematopoietic stem cell transplantation (HSCT).

228 sease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT).

229 in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients

230 D) is a notorious complication of allogeneic hematopoietic stem cell transplantation and causes disab

231 been reported after definitive therapy with hematopoietic stem cell transplantation and gene therapy

232 Trials of hematopoietic stem cell transplantation and gene therapy

233 systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase

234 Allogeneic hematopoietic stem cell transplantation combines cytored

235 outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation continue to impr

236 s in patients treated early after allogeneic hematopoietic stem cell transplantation do not support t

237 ve been successfully treated with allogeneic hematopoietic stem cell transplantation for more than 4

238 ute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from a homozygou

239 ents with naive repertoires at 9-12 mo after hematopoietic stem cell transplantation had increased di

240 amma (IFN-gamma) therapy is inefficient, and hematopoietic stem cell transplantation has a poor progn

241 The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in the generatio

242 Hematopoietic stem cell transplantation is a potential c

243 Allogeneic hematopoietic stem cell transplantation is hampered by c

244 ntrol in severely affected patients for whom hematopoietic stem cell transplantation is not available

245 Hematopoietic stem cell transplantation is the standard

246 n of protoporphyrin in the liver, LT without hematopoietic stem cell transplantation leaves the new l

247 Hematopoietic stem cell transplantation or gene therapy

248 signaling assays of 30 primary samples from hematopoietic stem cell transplantation patients with an

249 On the contrary, long-term allogeneic hematopoietic stem cell transplantation recipients other

250 All allogeneic hematopoietic stem cell transplantation recipients treat

251 rome but has not been assessed in allogeneic hematopoietic stem cell transplantation recipients.

252 Therefore, allogeneic hematopoietic stem cell transplantation should always be

253 oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survived compare

254 may lead to improved KIR-HLA mismatching in hematopoietic stem cell transplantation therapy for leuk

255 Until recently, hematopoietic stem cell transplantation was the only cur

256 The success of allogeneic hematopoietic stem cell transplantation, a key treatment

257 During hematopoietic stem cell transplantation, a substantial n

258 yndrome is a frequent complication following hematopoietic stem cell transplantation, dramatically in

259 t-related complications, donor selection for hematopoietic stem cell transplantation, evaluation of c

260 To highlight the utility for hematopoietic stem cell transplantation, frozen samples

261 d graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, suggesting norm

262 d with CNS disease and was reduced following hematopoietic stem cell transplantation, which is the on

263 t disease (cGVHD) is a major complication of hematopoietic stem cell transplantation.

264 al therapeutic target in patients undergoing hematopoietic stem cell transplantation.

265 vival may only be achievable with allogeneic hematopoietic stem cell transplantation.

266 Seven patients underwent hematopoietic stem cell transplantation.

267 as well as additional late effects following hematopoietic stem cell transplantation.

268 uartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.

269 erve leukemia remission and allow subsequent hematopoietic stem cell transplantation.

270 -versus-host disease in both solid organ and hematopoietic stem cell transplantation.

271 is a frequent condition following allogeneic hematopoietic stem cell transplantation.

272 dels of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.

273 pontaneous resolution to rapid relapse after hematopoietic stem cell transplantation.

274 Pulmonary complications are common following hematopoietic stem cell transplantation.

275 therapy to deplete the HSC niche to optimize hematopoietic stem cell transplantation.

276 stress syndrome development within 1 year of hematopoietic stem cell transplantation.

277 and 58 patients (2.7%) undergoing autologous hematopoietic stem cell transplantation.

278 dation involved chemotherapy with or without hematopoietic stem cell transplantation.

279 mune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% o

280 e rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will requ

281 subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may info

282 emia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induces a graft-

283 neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients.

284 ven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (

285 esidual disease response, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free su

286 ic patients with cancer and those undergoing hematopoietic stem-cell transplantation.

287 olved platelet transfusion in the setting of hematopoietic stem-cell transplantation.

288 nd death, can be halted only with allogeneic hematopoietic stem-cell transplantation.

289 y predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.

290 gh-throughput integration site analysis in a hematopoietic stem cell-transplanted humanized mouse mod

291 Four of the children received hematopoietic stem cell transplants and all showed poor

292 Twenty-one recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-e

293 The nature of hematopoietic stem cells under normal hematopoiesis rema

294 At the apex of the hierarchy, hematopoietic stem cells undergo a number of lineage com

295 perturbations can enhance fitness of clonal hematopoietic stem cells, which can impact outcome throu

296 Blood cells are derived from a common set of hematopoietic stem cells, which differentiate into more

297 atopoiesis results from somatic mutations in hematopoietic stem cells, which give an advantage to mut

298 e was reproducible in in vitro cultured cDKO-hematopoietic stem cells, which were significantly rescu

299 tachment could provide cancer stem cells and hematopoietic stem cells with a means to cycle from trop

300 d, we show how mRNA nanocarriers can program hematopoietic stem cells with improved self-renewal prop